
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
The American Journal of Managed Care
over 24 years ago
A New Era of Leadershipover 24 years ago
The Potential of Pill Splitting to Achieve Cost Savingsover 24 years ago
Rational Use of Antibiotics to Treat Respiratory Tract Infectionsover 24 years ago
Reducing Cesarean Delivery Rates in Managed Care Organizations





